LB Pharmaceuticals is a late-stage clinical biopharmaceutical company developing a single drug candidate, LB-102, for neuropsychiatric disorders. LB-102 is a methylated derivative of amisulpride, a second-generation antipsychotic widely used outside the U.S. but never FDA-approved. LB Pharmaceuticals designed LB-102 to improve on amisulpride by enhancing blood-brain barrier permeability, enabling much lower doses and once-daily dosing. The primary target indication is schizophrenia, where LB-102 completed a positive Phase 2 trial (NOVA-1) and initiated Phase 3 (NOVA-2) in March 2026, with topline data expected in H2 2027. The FDA has indicated that NOVA-1 may count as one of two pivotal trials required for NDA approval. Beyond schizophrenia, LB Pharmaceuticals is running Phase 2 trials in bipolar depression and plans to initiate a Phase 2 in adjunctive major depressive disorder, mirroring the multi-indication playbook of leading branded antipsychotics. The company also has early-stage plans for a long-acting injectable formulation, which would be the only benzamide-class LAI. LB Pharmaceuticals has no approved products or revenue, and funds operations through equity raises, including its 2025 Nasdaq IPO. If LB-102 is approved, the company plans to commercialize in the U.S. directly and pursue partnerships for ex-U.S. markets.